Status:
UNKNOWN
ADR-002K for Patients With Ischemic Cardiomyopathy Who Undergo Coronary Artery Bypass Surgery
Lead Sponsor:
Osaka University
Collaborating Sponsors:
Rohto Pharmaceutical Co., Ltd.
Conditions:
D017202
Eligibility:
All Genders
20-80 years
Phase:
PHASE1
Brief Summary
Ischemic cardiomyopathy undergoing coronary artery bypass surgery
Eligibility Criteria
Inclusion
- Patients who are clinically diagnosed with ischemic cardiomyopathy and receive CABG
- Patients with a left ventricular ejection fraction of 40% or less by cardiac ultrasonography within 4 weeks before obtaining consent
- Others
Exclusion
- Patients who have a combination of cardiovascular disease such as severe organic valvular disease or aortic aneurysm determined by investigator or co-investigator to affect clinical trial procedure
- Patients whose participation in a clinical trial is considered inappropriate at the discretion of the investigator or co-investigator
- Others
Key Trial Info
Start Date :
November 27 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2021
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT04695522
Start Date
November 27 2019
End Date
October 31 2021
Last Update
January 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Osaka University Hospital
Suita, Osaka, Japan, 5650871